Amir Gross is a serial entrepreneur, a MedTech executive, and a visionary who passionately builds structural heart technology companies from the ground up—from a napkin sketch to successful exits ($1Bn). Amir is CEO of Cardiovalve, a leading developer of replacement mitral and tricuspid valve systems. Cardiovalve was acquired by Venus MedTech Inc. (Venus MedTech, 2500.HK) in an exit of $300M in 2022. In addition to his role as CEO, Amir leads Venus Medtech’s global heart valve innovation center. At the center, Amir heads local incubation of innovative therapeutic technologies, including a new generation of valves for the treatment of aortic regurgitation, and the application of digital health technology to heart valve systems. Previously, Amir founded and was CEO of Valtech Cardio until it was acquired by one of the largest medical device companies in the world, Edwards Life Sciences (NYSE: EW) in a $700M exit. As CEO of Valtech, Amir led a team of 70 experts to create something previously seen as impossible: repairing one of the main valves in the heart by inserting a small catheter in a patient’s leg, with no need for open heart surgery.